Erbitux Patent Holder Yeda Responds to ImClone Suit
This article was originally published in The Pink Sheet Daily
Executive Summary
Company demands treble damages and non-exclusive licensing deal.
You may also be interested in...
ImClone Finds Itself Facing Another Erbitux Patent Suit
Abbott alleges cell line used to manufacture cetuximab violates one of its patents.
ImClone Finds Itself Facing Another Erbitux Patent Suit
Abbott alleges cell line used to manufacture cetuximab violates one of its patents.
ImClone Reports Promising Erbitux First-Line Colorectal Cancer Results
Company will present data from the Phase III CRYSTAL study at ASCO in June.